Esperion Therapeutics Inc.

05/15/2021 | Press release | Distributed by Public on 05/15/2021 10:28

Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21